

## Contents

---

<i>Foreword</i> .....	(v)
<i>Preface</i> .....	(vii)
<i>Contributors</i> .....	(ix)

### Chapter – 1

#### Controlled Release Products

1.1 Introduction .....	1
1.2 Advantages and Benefits .....	4
1.3 Disadvantages and Problems .....	6
1.4 Classification of CR Systems Based on Fabrication Techniques .....	7
1.4.1 Diffusion Controlled Products .....	7
1.4.1.1 Matrix controlled systems .....	7
1.4.1.2 Reservoir controlled systems .....	9
1.4.2 Dissolution-controlled Products .....	10
1.4.2.1 Matrix dissolution products .....	10
1.4.2.2 Reservoir dissolution-controlled systems .....	10
1.4.3 Dissolution and diffusion controlled products (pore forming method) .....	10
1.4.4 Erosion Products .....	11
1.4.5 Water penetration controlled systems .....	12
1.4.5.1 Swelling controlled systems .....	12
1.4.5.2 Osmotic controlled systems .....	12

1.4.6 Drug Covalently Linked to the Polymer .....	16
1.4.7 Ion Exchange Resins .....	17
1.4.8 Responsive Drug Delivery Systems .....	18
1.5 Design of Sustained Release Dosage Forms .....	19
1.6 CR Formulations Used in Different Routes of Administration and the Salient Features .....	23
1.6.1 Oral CR formulations .....	23
1.6.1.1 Currently marketed oral CR products .....	24
1.6.1.2 Special features in the design of oral CR products .....	25
1.6.1.3 Techniques of preparation and manufacture .....	32
1.6.2 Parenteral CR Formulations .....	38
1.6.2.1 Currently marketed parenteral CR products .....	49
1.6.2.2 Special Features in the Design of Parenteral CR Products .....	51
1.6.2.3 Techniques of Preparation and Manufacture .....	58
1.7 Testing of CR Systems .....	69
1.8 Conclusions .....	73
<b>References .....</b>	<b>74</b>

## **Chapter – 2**

### **Gastroretentive Drug Delivery Systems**

2.1 Introduction .....	77
2.2 Basic Anatomy and Physiology of Stomach .....	80
2.3 Factors Influencing Gastric Retention Time (GRT) .....	85
2.4 Strategies for Gastroretentive Drug Delivery Systems .....	89
2.4.1 Floating Drug Delivery Systems .....	90
2.4.1.1 Noneffervescent/ Swellable FDDS .....	90
2.4.1.2 Effervescent systems .....	94

2.4.1.3 Multiple Unit Floating Systems .....	97
2.4.1.4 Gas-generating Systems .....	98
2.4.1.5 Hollow Microspheres .....	101
2.4.1.6 Floating alginate beads .....	104
2.4.1.7 Expandable/Swellable drug delivery systems .....	105
2.4.2 Superporous Hydrogels .....	108
2.4.3 Mucoadhesive or bioadhesive systems .....	109
2.4.4 Magnetic Systems .....	110
2.4.5 Use of Passage Delaying Agents .....	111
2.5 Drugs Explored for GRDDS .....	111
2.6 Evaluation of Gastroretentive Drug Delivery Systems .....	113
2.7 Marketed Products of GRDDS .....	118
2.8 Case study (Acta Pharm, Suresh Bandari et al., 2010) .....	120
<b>References .....</b>	<b>128</b>

## Chapter – 3

### Buccal Drug Delivery Systems

3.0 Introduction .....	139
3.1 Oral Mucosa .....	142
3.1.1 Anatomy of the Oral Mucosa .....	142
3.1.2 Biochemistry of the Oral Mucosa .....	144
3.1.3 Absorption Pathways .....	145
3.1.4 Permeability Barrier of the Oral Mucosa .....	147
3.1.5 Oral Mucosal Permeation Enhancers .....	148
3.2 Mucoadhesion/Bioadhesion .....	150
3.2.1 Definition .....	150
3.2.2 The Mucoadhesive/Mucosa Interaction .....	150

3.3	Factors Affecting Muco/Bioadhesion in the Oral Cavity	156
	3.3.1 Polymer-Related Factors	156
	3.3.2 Environmental Factors	158
3.4	Mucoadhesive polymers used in the buccal delivery	159
	3.4.1 Desired characteristics	159
	3.4.2 Classification	160
3.5	Novel Second-generation Mucoadhesives	161
	3.5.1 Lectins	161
	3.5.2 Bacterial Adhesions	162
	3.5.3 Thiolated Polymers	162
3.6	Dosage Forms for Buccal Drug Delivery	163
3.7	Tablets	164
3.8	Buccal Patches/films	165
	3.8.1 Solvent Casting Technique	165
	3.8.2 Hot Melt Extrusion Technique	167
3.9	Evaluation	172
	3.9.1 Moisture Absorption Studies for Buccal Patches	172
	3.9.2 Swelling Studies for Buccal Tablets	172
	3.9.3 Surface pH Study	173
	3.9.4 Measurement of Mechanical Properties	173
	3.9.5 <i>In vitro</i> Bioadhesion Measurement	174
	3.9.6 <i>Ex Vivo</i> Residence Time	175
	3.9.7 <i>In vivo</i> Residence Time	176
	3.9.8 Permeation Studies	176
	3.9.8.1 <i>Ex Vivo</i> Permeation	176
	3.9.8.2 <i>Ex Vivo</i> Drug Permeation Studies	177
	3.9.9 Buccal Absorption Test	177
	3.10 Research Case Studies for Buccal Drug Delivery	180
	3.10.1 Case study (Patch)	180
	3.10.2 Case study: Buccal tablet	193
3.11	Conclusions	198
	<b>References</b>	<b>199</b>

## **Chapter – 4**

### **Multiple Emulsions**

4.1 Introduction .....	213
4.2 Nomenclature (13) .....	215
4.3 Advantages .....	215
4.4 Preparation Techniques .....	217
4.4.1 Two Step Emulsification Method (13) .....	217
4.4.2 Phase Inversion Method (one step method) .....	218
4.4.3 Membrane Emulsification Technique .....	219
4.4.4 Microchannel emulsification .....	220
4.5 Formation of Multiple Emulsions .....	220
4.6 Stability of Multiple Emulsions .....	224
4.7 Factors Controlling the Stability of Multiple Emulsions .....	227
4.8 Mechanisms of Instability (19) .....	230
4.9 Stabilization of Multiple Emulsion .....	230
4.9.1 Stabilization by Forming Polymeric Gel (19) .....	230
4.9.2 Stabilization by Increased Viscosity .....	231
4.9.3 Modulating Surfactant Concentration .....	232
4.9.4 Formation of Interfacial Complex Films .....	233
4.10 Characterization .....	234
4.11 Drug Delivery Mechanisms .....	238
4.12 Bioavailability .....	240
4.13 Applications of Multiple Emulsions .....	241
4.14 Routes of Administration .....	248
4.15 O/W/O Double Emulsions .....	249
<b>References .....</b>	<b>250</b>

## **Chapter – 5**

### **Nanoemulsions**

5.1 Introduction .....	259
5.2 Structure of Nanoemulsion .....	263

5.3	Preparation of Nanoemulsions .....	265
5.3.1	High-Energy Emulsification Methods .....	265
5.3.1.1	Devices and processes .....	265
5.3.1.2	The choice of surfactants, monomers, aqueous and oily phases .....	266
5.3.1.3	On the potentialities, advantages and disadvantages of high-energy method .....	267
5.3.2	Low-Energy Emulsification Methods .....	267
5.3.2.1	Spontaneous nano-emulsification .....	268
5.3.2.2	The emulsion inversion point (EIP) method ..	271
5.3.2.3	Phase inversion temperature (PIT) method ..	272
5.4	Drug Loading in Nanoemulsions .....	276
5.5	Emulsion Destabilization .....	278
5.6	Stability of Nanoemulsions .....	282
5.7	Ostwald Ripening .....	285
5.8	Advantages of Nanoemulsion in Drug Delivery .....	287
5.8.1	Solubilization of Poorly Soluble Drugs .....	287
5.8.2	Reduced Pain/Irritation .....	287
5.8.3	Reduced Toxicity of Drug .....	288
5.8.4	Improved Pharmacokinetics .....	289
5.8.5	New Method of Delivery .....	291
5.8.6	Drug Targeting .....	292
5.8.6.1	Active Targeting .....	292
5.8.6.2	Passive Targeting .....	293
5.8.7	Multiple Functionality .....	294
5.8.8	New Therapies .....	295
5.9	Characterization of Nanoemulsion .....	295
5.9.1	Dynamic light scattering .....	295
5.9.2	Electrical conductivity measurements .....	296
5.9.3	Particle Size Distribution .....	296
5.9.4	Rheology .....	296
5.9.5	Refractive index .....	296

---

5.10 Nanoemulsion in Novel Drug Delivery .....	296
5.11 Various Parenteral Application of Nanoemulsion .....	301
<b>References .....</b>	<b>302</b>

## **Chapter – 6**

### **Microspheres**

6.1 Introduction .....	309
6.2 Pharmaceutical Applications of Microspheres .....	312
6.2.1 Microparticulates for Gastrointestinal Delivery .....	312
6.2.2 Parenteral Microspheres .....	315
6.2.3 Microspheres for Nasal Administration .....	318
6.2.4 Microspheres for Pulmonary Administration .....	320
6.2.5 Bioadhesive Microspheres .....	323
6.2.6 Microspheres for Special Purposes .....	324
6.3 Polymers Used in the Preparation of Microspheres .....	325
6.3.1 Cellulose based Microparticles .....	326
6.3.2 Microspheres Based on Chitosan .....	327
6.3.3 Albumin microspheres .....	330
6.3.4 Eudragit Microspheres .....	331
6.3.5 Polylactide-co-glycolide Microspheres .....	333
6.3.6 Polycaprolactone Microspheres .....	336
6.3.7 Triglyceride Lipospheres .....	337
6.4 Fabrication of Microspheres .....	337
6.4.1 Emulsion Solvent Evaporation and its Modifications ..	338
6.4.2 Spray Drying .....	355
6.4.3 Air Suspension .....	362
6.4.4 Coecervation-Phase Separation .....	363
6.5 Characterization of Microspheres .....	366
6.6 Conclusions .....	373
<b>References .....</b>	<b>374</b>

## Chapter –7

### **P-glycoprotein and CYP3A Limiting Oral Drug Absorption**

7.1 Introduction .....	379
7.2 Factors Influencing Oral Bioavailability of Drugs .....	380
7.3 Efflux Mechanisms as Barriers to Intestinal Absorption .....	381
7.4 CYP 3A and Oral Bioavailability .....	393
7.5 Models to Screen CYP3A and/or P-gp Modulators as Oral Bioavailability Enhancers .....	395
7.5.1 Experimental Models .....	395
7.5.1.1 <i>In Vitro</i> Models .....	396
7.5.1.2 <i>In Situ</i> Models .....	401
7.5.1.3 <i>In Vivo</i> Models .....	402
7.6 Correlation of <i>In Vivo</i> and <i>In Vitro</i> Screening Models .....	404
7.7 MDR and CYP3A4 Mediated Drug–Herbal Interactions ....	409
<b>References .....</b>	<b>414</b>

## Chapter –8

### **Liquid Crystals**

8.1 Introduction .....	431
8.2 Structure .....	435
8.3 Type of Liquid Crystal .....	438
8.3.1 Thermotropic Liquid Crystals .....	438
8.3.1.1 Smectic .....	439
8.3.1.2 Nematic .....	439
8.3.1.3 Columnar .....	440
8.3.2 Lyotropic Liquid Crystals .....	441
8.3.2.1 Lamellar .....	443
8.3.2.2 Hexagonal .....	443
8.4 Physicochemical Properties of Liquid Crystal .....	445
8.4.1 Properties of Liquid Crystal .....	445



8.4.2	Effect of Various Factors on Properties of Liquid Crystal .....	446
8.4.2.1	Effect of Concentration .....	446
8.4.2.2	Effect of Temperature .....	447
8.4.2.3	Effect of Energy and Entropy .....	447
8.4.2.4	Effect of Salt .....	448
8.4.2.5	Effect of pH .....	449
8.4.3	Method for Characterization of Liquid Crystal .....	449
8.4.3.1	Macroscopic View .....	449
8.4.3.2	X-Ray Diffraction .....	449
8.4.3.3	Differential Scanning Calorimetry .....	449
8.5	Application .....	450
8.5.1	Pharmaceutical Application .....	450
8.5.1.1	Solubility Enhancement of Poorly Soluble Drugs .....	451
8.5.1.2	Controlled/Sustained Release of Drug .....	452
8.5.1.3	Stability of Drug .....	455
8.5.1.4	Effect of Base and Salts from Different Liquid Crystalline Structures on Drug Release Profile .....	456
8.5.1.5	Photopolymerization of Lyotropic Liquid Crystalline Systems: A New Route to Nanostructured Materials .....	457
8.5.1.6	Nanostructured Hexosome for Injectable Drug Delivery .....	457
8.5.1.7	Temperature modulated drug permeation through liquid crystal embedded cellulose membranes .....	458
8.5.1.8	Liquid Crystal for Treatment of Cancer and Other Disease .....	459
8.5.2	Non-Pharmaceutical Application .....	459
8.5.2.1	Liquid Crystal in Cosmetics .....	459
8.5.2.2	Liquid Crystal in Soap Industries .....	459
8.5.3.3	Liquid Crystals in Optics .....	460
8.6	Conclusion .....	460
	<b>References .....</b>	<b>460</b>

## Chapter –9

### Chirality in Drug Development

9.1 History of Chirality .....	467
9.2 Nomenclature .....	468
9.3 Introduction .....	472
9.4 Pharmacological difference between enantiomers .....	476
9.5 Chiral Drugs in Biological Systems .....	478
9.6 Importance of Chirality in Drugs .....	480
9.7 Thalidomide a Typical Example The First Appearance of Thalidomide .....	487
9.8 Chiral Chromatography .....	491
9.9 Chiral Drug Formulation .....	504
9.10 Conclusions .....	514
<b>References .....</b>	<b>515</b>
<b>Index .....</b>	<b>523</b>